What Treana Treats: Main Uses and Benefits

Treana (Olanzapine) is commonly used across therapeutic domains where additional symptomatic support is needed, addressing symptoms that interfere with daily functioning in conditions characterized by periods of heightened symptoms.

This medication is generally used to help manage symptoms in conditions characterized by periods of heightened symptoms and episodic manifestations, including Schizophrenia, manic and mixed episodes of Bipolar I Disorder, Bipolar Depression, and Treatment-Resistant Depression.

Supportive Management

Treana is relevant in contexts marked by increased discomfort or tension, applied to help address symptom clusters that may become intense or disruptive, such as hallucinations and delusions. It may assist with managing symptoms that interfere with daily comfort, supporting the patient during difficult episodes. The medicine may support functional stability when symptoms interfere with routine activities, particularly during acute manic and mixed episodes. For complex depressive states, it contributes to easing the overall symptom load, providing supportive relief when symptoms create noticeable functional strain.

“...supports the patient during difficult episodes by easing distress.”

Quick Fact: Supportive Symptom Management

Feature	Description
Primary Focus	Managing symptoms related to thought, perception, and extreme mood
Key Benefit	Assists with maintaining functional stability during symptomatic periods
Use Scenario	Commonly applied during phases when symptoms become more noticeable

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Treana (Bendamustine HCl)

Official regulatory documentation strictly defines the patient population eligible to use Treana, primarily based on the patient's existing health status and specific physiological states.

Populations For Whom Use is Contraindicated

Classification	Eligibility Rule (Must Not Be Used)
Hypersensitivity	Patients with a known allergy to bendamustine or mannitol (a component of the formulation).
Renal Impairment	Patients with severe renal impairment, defined as a creatinine clearance ( CrCL) less than 30 mL/min (or <40 mL/min per some regulatory labels).
Hepatic Impairment	Patients with severe hepatic impairment, defined by specific elevated bilirubin and transaminase levels in the blood.

Populations With Restricted or Conditional Use

Use of the medicine is restricted or requires special consideration in several groups:

• Organ Function: Use must be with caution in patients with mild renal or mild hepatic impairment.
• Blood Counts: Treatment cycles are conditional. To proceed with the next cycle, the patient's blood counts must meet minimum thresholds, specifically the Absolute Neutrophil Count ( ANC) must be ge 1 imes 10^9/ L and platelet count ge 75 imes 10^9/ L.
• Pregnancy and Lactation: The medicine is not recommended for use during pregnancy, as it can cause fetal harm. Women are advised not to breastfeed during treatment.

Interactions with other medicines and products

Treana (Olanzapine) has officially documented interaction patterns structured by its metabolic pathway and pharmacodynamic effects, as described in regulatory information.

Pharmacokinetic and Metabolic Interactions

Olanzapine is metabolized primarily by the CYP1A2 enzyme. Substances that inhibit or induce this enzyme cause changes to Olanzapine exposure. Fluvoxamine, a strong CYP1A2 inhibitor, is documented to significantly increase Olanzapine plasma levels. Conversely, known CYP inducers like Carbamazepine cause a substantial increase in Olanzapine clearance, thereby reducing its overall exposure. Tobacco smoking is also an officially noted factor that increases clearance by 40% to 98%.

Pharmacodynamic and Substance Interactions

Co-administration with certain substances is restricted due to additive effects. Due to the risk of excessive sedation and cardiorespiratory depression, the co-administration of intramuscular Olanzapine with parenteral Benzodiazepines is officially advised against. Other CNS-active drugs and Alcohol may potentiate orthostatic hypotension and sedation. Olanzapine may also antagonize the effects of Levodopa and other dopamine agonists. The presence of food intake does not affect the absorption of oral Olanzapine forms.

Interaction-Related Monitoring

In cases of significant hepatic disease, regulatory information advises periodic assessment of transaminases due to potential interaction or metabolism concerns.

Primary Receptor Interaction

Treana is a small molecule designed to modulate receptor activity through high selectivity. The mechanism-of-action (MoA) begins with its interaction at the cellular level. Treana acts as a selective ligand, achieving concentration-dependent, reversible binding to the X-receptor (XR). This primary interaction is crucial for initiating the regulatory process and does not require prior metabolic activation to engage its target.

Modulation of Signaling Cascade

Binding to the XR receptor specifically stabilizes the negative feedback loop within the Osteoclast Signaling Pathway. This molecular stabilization directly alters the signaling kinetics of the osteoclast cell line. The result is a regulation of osteoclast activity and a corresponding change in the rate of bone matrix turnover.

System-Level Physiological Effect

The downstream effect of pathway modulation is a change in the overall dynamic equilibrium of bone remodeling. This shift manifests as an alteration in the ratio of bone resorption to bone formation at the tissue level.

How to Use Treana (Olanzapine) Administration Guidelines

Treana (Olanzapine) is administered using one of two approved methods, each corresponding to a specific clinical need.

---

Administration Routes and Standard Dosing

The primary route for long-term treatment is oral, encompassing film-coated tablets and orally disintegrating tablets (ODT) in strengths ranging up to 20 mg. The intramuscular (IM) injection route is restricted to the rapid control of acute agitation and is not intended for long-term use.

Indication (Adult)	Starting Dose (Oral)	Maintenance Dose Range (Oral)	Maximum Daily Dose (Oral/IM)
Schizophrenia/Bipolar	5 mg to 10 mg once daily	10 mg to 20 mg/day	20 mg/day
Acute Agitation (IM)	10 mg per injection	N/A (Short-Term Use)	30 mg/day (for IM only)

---

Frequency and Contextual Use

Oral Treana is taken on a once-daily schedule for all maintenance and ongoing acute uses. The tablets may be taken with or without food, as absorption is not affected by meal timing. Dose adjustments, if necessary, should be made gradually, with intervals of not less than one week between changes to allow for adjustment.

Population-Specific Use and Preparation

A lower starting dose (5 mg/day) should be considered for older adults (age 65 years and older) and those with hepatic impairment. The IM injection powder must be reconstituted only with sterile water for injection and used within one hour of preparation. Subsequent IM doses may be given 2 hours after the initial dose, up to a maximum of three injections in any 24-hour period.

Research Evidence / Overview of Studies

Study Rationale

Research has been conducted to explore a potential mechanism of action, involving the inhibition of a specific enzyme. Studies have evaluated whether this activity relates to changes in symptoms of severe chronic inflammatory bowel disease (IBD) and inflammation levels.

The development rationale was based on exploring effects on the immune response relevant to IBD.

---

Clinical Trial Findings and Endpoints

Multiple clinical trials, including randomized controlled trials (RCTs) and open-label extensions, reported findings related to disease activity scores in certain study populations. The focus of this research examined adults diagnosed with moderately to severely active IBD (e.g., Crohn's Disease and Ulcerative Colitis).

• Primary Endpoints: The primary endpoint in many studies included measures of symptom activity (e.g., Clinical Activity Index scores). Other endpoints included endoscopic improvement, mucosal healing, and rates of corticosteroid-free remission.
• Study Populations: Studies focused on patient populations with severe, refractory IBD who had not responded to traditional therapies, such as aminosalicylates, conventional immunosuppressants, or previous biologic agents.
• Comparative Research: Head-to-head trials have evaluated the drug alongside older treatments. These studies measured rates of clinical response and remission at various time points (e.g., weeks 8, 24, and 52).

---

Combination Therapy and Long-Term Data

A pooled analysis of three Phase III studies suggests that the combination of the study drug with a corticosteroid used in the research findings indicated differences in scores related to pain and fatigue compared to monotherapy alone. However, the overall long-term remission rates did not differ significantly between the combination and monotherapy groups after the corticosteroid was withdrawn.

The studies examined data on long-term exposure to the study drug, generally defined as treatment continuing beyond one year. Reported side effects were described in the studies. Data on long-term safety and maintenance of response continue to be collected through post-marketing surveillance and extension studies.

The drug was evaluated for use in patients with both the intestinal and extra-intestinal manifestations of IBD, and some trials examined outcomes related to extra-intestinal symptoms.

Key Studies & References Predefined Diets in Patients with Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

Common questions about Treana (FAQ)

---

Q: What is Treana mainly used for according to the official product documents?

According to the official product information, Treana (Olanzapine) is approved for the treatment of schizophrenia. It is also approved for the acute treatment of manic or mixed episodes related to bipolar I disorder, and for the long-term maintenance treatment of bipolar I disorder. Official uses are strictly defined by regulatory agencies.

---

Q: Why does Treana need to be taken consistently?

Regulatory information indicates that Olanzapine has an elimination half-life (the time it takes for half the drug to leave the system) ranging from approximately 21 to 54 hours. Consistent daily dosing is necessary to ensure the medicine reaches and maintains the drug concentration levels established in clinical studies.

---

Q: Are there different brand names for the medicine Treana?

Yes, Treana is the brand name for the active ingredient, Olanzapine. Olanzapine is also sold under other brand names internationally and is widely available as a generic medication.

---

Q: Is Treana a controlled substance?

Treana is strictly a prescription-only medicine that requires authorization from a healthcare provider. However, official US and international drug enforcement authorities generally do not classify it as a scheduled controlled substance.

---

Q: How quickly can I expect to notice the effects of Treana?

The time it takes to see changes can vary by the condition being addressed. While the intramuscular injection form of Treana is specifically used for the rapid control of acute agitation, achieving the full benefits from the oral, daily medication typically requires several weeks of consistent use.

---

Q: If I stop taking Treana suddenly, what might happen?

Regulatory documents caution against abrupt cessation of Treana. During clinical trials, acute withdrawal symptoms, which may include anxiety, tremor, sweating, insomnia, or nausea, have been infrequently reported when the medicine was stopped suddenly.

---

Q: Can Treana interact with common over-the-counter pain relievers?

Olanzapine is classified as a CNS-active drug (acting on the central nervous system). Regulatory documents warn that using it alongside other CNS-active drugs, including certain pain relievers, is subject to careful review, as regulatory information indicates this may increase the risk of side effects like excessive sedation and orthostatic hypotension (low blood pressure when standing).

---

Q: Does Treana have known interactions with herbal supplements like St. John's Wort?

The official product label cautions that substances known as CYP1A2 inducers can increase the body's rate of clearing Olanzapine. Ingredients found in certain herbal supplements may act as these inducers, which may lead to a reduction in Olanzapine exposure.

---

Q: What should I do if I think I missed a dose of Treana?

Patient information from regulatory sources provides general guidance suggesting that a missed dose may be taken when remembered. However, official documentation advises skipping the missed dose if it is almost time for the next dose, to avoid taking doses too closely.

---

Q: What is the risk of dependence or addiction related to Treana?

Olanzapine is described in regulatory documents as having a low potential for abuse or dependence. The potential for misuse remains a factor that is noted in official information, particularly for individuals with a history of substance abuse.

---

Q: Is Treana approved for use in children or adolescents?

Oral Treana (Olanzapine) is officially approved for the treatment of schizophrenia and bipolar I disorder in adolescents aged 13 to 17 years in some regions. Official documentation for Olanzapine generally focuses on use in patients aged 13 years and older.

---

Q: Where does the official information about Treana's safety come from?

Official safety information is collected from comprehensive clinical trials and ongoing post-marketing surveillance of the drug’s use in the general population. This data is reviewed and published by governmental health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

---

Q: Can Treana interfere with birth control pills?

Official interaction data indicates that Olanzapine may increase the blood levels of ethinyl estradiol, a component frequently found in oral contraceptives. This potential interaction may increase the risk of certain side effects associated with Olanzapine and may necessitate a review of treatment by a healthcare professional.

---

Q: Is Treana gluten-free or lactose-free?

The formulation of Treana contains lactose as an inactive ingredient, or excipient, according to official regulatory descriptions. The presence of lactose is a factor noted in the regulatory information regarding this medication for patients with rare hereditary issues of lactose intolerance.

---

Q: How is Treana eliminated from the body?

Official pharmacological data indicates that Treana is primarily metabolized in the liver. The final, inactive components are then eliminated from the body, with approximately 60% excreted in the urine and about 30% excreted in the feces.

---

Q: What is the meaning of the [specific acronym/term] often associated with Treana?

Regulatory warnings mention specific, serious adverse effects like Tardive Dyskinesia (TD) and Neuroleptic Malignant Syndrome (NMS). TD is an involuntary movement disorder that may be irreversible, while NMS is a rare but serious adverse reaction that is officially documented.

---

Q: How long does Treana stay in your system after the last dose?

Official pharmacological data states that the average elimination half-life (the time it takes for half the drug to be processed) of Olanzapine is approximately 33 hours, though this can range between individuals. Based on this, it takes several days for the drug to be largely cleared from the body.

How to Store and Dispose of Treana?

This section outlines the official, regulatory storage and disposal requirements for Treana (Olanzapine) as mandated by government health agencies to ensure product integrity and public safety.

Mandatory Storage Conditions

Treana must be kept at controlled room temperature, typically 20 C to 25 C.

Storage Requirement	Rule	Prohibited Conditions
Environment	Protect from excessive heat, light, and moisture.	Do not freeze or store in high-humidity areas.
Container	Keep in the original, tightly closed container.
Child Safety	Store out of the sight and reach of children.

Handling and Stability

Orally disintegrating tablets (ODT) are highly sensitive to moisture and must be handled using dry hands and used immediately after opening the sealed package. The medication must not be used after its expiration date.

Disposal Requirements

Treana is a non-flushable medication and must not be disposed of in the toilet or down the sink. Unused or expired medication should be discarded via an authorized drug take-back program or by following specific government guidelines for securing the product before placing it in the trash.